Medaus Recalls Tryptophan Vials Due to Sterility Assurance Concerns
Medaus, Inc. is recalling Tryptophan 10mg/mL vials because the company cannot ensure the product is sterile. The recall affects 10mL and 50mL vials distributed in the U.S., Japan, and New Zealand.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, an FDA Class II recall involving a significant hazard such as lack of sterility assurance in an injectable product warrants a score of 4 (Severe).
Plain-English summary
Medaus, Inc. is recalling Tryptophan 10mg/mL (PF) in 10mL and 50mL vials. The recall was initiated because the company lacks assurance of the sterility of the product. The affected lots include Lot # 160125-14 (Best Use Date: 07/23/16) and Lot # 160315-12 (Best Use Date: 09/11/16).
The recalled product was distributed nationwide in the United States, as well as in Japan and New Zealand. The total quantity involved is 2,000 mL in vials.
Consumers and healthcare providers should stop using the affected vials and contact Medaus, Inc. for further instructions or a refund.
The recalled product
- Product
- TRYPTOPHAN 10MG/ML (PF), In a) 10ML Vials and b) 50ML Vials, MEDAUS PHARMACY
- Manufacturer
- Medaus, Inc.
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (5)
- a) Lot #: 160125-14
- BUD: 07/23/16
- Lot #: 160315-12
- BUD: 09/11/16. b) Lot #: 160125-14
- BUD: 09/11/16.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 88 recalled by Medaus, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 88 products in this recall →Related recalls
Same manufacturer · Medaus, Inc.
See all →- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Testosterone Cypionate Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Taurine Vials Due to Lack of Sterility Assurance
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls Lipo-Injection Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2016-07-20
- SevereMedaus Recalls B-Complex Vials Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
Same hazard · lack of sterility
See all →- SevereGentle Eyes Lubricant Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereWalgreens Lubricant Eye Drops Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-09-30
- SevereClear Eyes Redness Relief Eye Drops Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
Similar recalls
- SevereMedaus Recalls Taurine 50 mg/mL PF Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls L-Glutathione Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Pyridoxine HCL Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Testosterone Cyp 200 mg/mL Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Magnesium Chloride Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMedaus Recalls Lipo-Injection Due to Sterility Concerns
FDA (Drugs) · 2013-09-25